報價延遲最少15分鐘:2025/07/20 19:03 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
37.23 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.29/-5.57
|
|
企業價值
5.40B
|
| 資產負債 |
|
每股賬面淨值
-2.23
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
18.47M
|
|
每股收益
0.07
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 19:03 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
